Tunicamycin blocks neuritogenesis and glucosamine labeling of gangliosides in developing cerebral neuron cultures.

Fetal cerebral neurons at the initiation of active neurite outgrowth in culture incorporate 4-fold more [3H]glucosamine into glycoproteins than into the cellular lipid fraction. After 8 days or longer, when a well-developed fiber network is apparent, lipids are labeled more extensively than the glycoproteins. Labeling of the latter is inhibited 95% and 89% by 0.5 microgram of tunicamycin per ml added to 1-day-old and 8-day-old cultures, respectively. Labeling of glycolipids is inhibited 30% in 1-day-old and 86% in 8-day-old cultures. Tunicamycin blocks incorporation of glucosamine label into practically all ganglioside species except for a resorcinol-positive, sialidase-sensitive band tentatively identified as GQ1b tetrasialoganglioside (Svennerholm ganglioside nomenclature). It also substantially reduces binding of 125I-labeled tetanus toxin to intact cells. There is 14% and 27% reduction in the total ganglioside sialic acid content in 1-day-old and 8-day-old cells treated for 24 hr with 0.5 microgram of tunicamycin per ml, but no substantial compositional changes are encountered. Tunicamycin blocks neurite outgrowth when added to cells soon after plating but causes no retraction or losses of fibers once the fiber network is established. Therefore, inhibition of neurite outgrowth by tunicamycin is not due to an effect on cellular gangliosides but can be correlated to an inhibition of protein glycosylation.